Create
Query
event_store.db
—
signals
actions
agent_runs
approvals
artifacts
attention_candidates
commitments
constraints
conversation_compaction
conversation_state
conversation_turns
dead_letters
decisions
deliveries
effects
email_messages
email_reply_drafts
email_threads
entities
entity_aliases
entity_tags
episode_context_index
episodes
event_subjects
events
events_archive
fact_sources
facts
inbox_items
inbox_links
intel_narrative_members
intel_narratives
jobs
leader_leases
links
memory_candidates
memory_embeddings
memory_items
memory_items_fts
(v)
memory_items_fts_config
memory_items_fts_data
memory_items_fts_idx
opportunity_memory
pending_interactions
proposal_sources
proposals
reminders
schedules
schema_migrations
signal_candidates
signal_fps
signals
sms_conversations
sms_messages
sms_reply_drafts
source_cursors
sources
sqlite_sequence
sqlite_stat1
stream_cursors
threads
watchers
Toggle helper tables
memory_items_fts_content
memory_items_fts_docsize
memory_items_fts_segdir
memory_items_fts_segments
memory_items_fts_stat
Structure
Content
Query
Insert
Drop
Import
Export
Update row sig_d5c15e7f7c10 in signals
id
sig_d5c15e7f7c10
Primary key.
TEXT
event_id
470569
TEXT NOT NULL
watcher_id
NULL
TEXT
signal_type
discovery_sec_filing_delta
TEXT NOT NULL
value
{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","company":"Roivant Sciences Ltd.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","article_chars":2030,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_bd490222a49e5233","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","content_type":"text/plain","enriched_at":"2026-04-21T10:44:50.605378+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt","source_event_id":"evt_0d0e7b9d1c2e","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"84b4e8599be613ba","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-20","2026-04-21T03:09:54.871544+00:00","2026-04-16"],"entities":[{"asset_class":"equity","name":"Roivant Sciences Ltd.","relevance":"high","symbol":"ROIV","type":"issuer"},{"asset_class":"equity","name":"Matthew Gline","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Jo Chen","relevance":"low","symbol":"","type":"attorney_in_fact"}],"event_type":"other","information_gaps":["No prior known state is provided in the signal, so the specific 'delta vs prior' change cannot be determined from the provided text alone.","The filing text excerpt does not explicitly state whether there were any purchases or other transactions besides the reported sale.","The excerpt does not provide the total dollar value of the transaction(s)."],"key_facts":["SEC filing type: Form 4.","Issuer: Roivant Sciences Ltd.","Issuer ticker/symbol shown in filing values: ROIV.","Reporting person: Matthew Gline (listed as CEO).","Conformed period of report (transaction date): 2026-04-16.","Filed as of date: 2026-04-20.","Reported transaction: sale of 289,774 common shares.","Weighted average price reported in column 4: $29.16.","Shares were sold in multiple transactions at prices ranging from $28.98 to $29.36 (inclusive).","Undertaking included to provide full information on number of shares sold at each separate price within the range upon request."],"numeric_claims":[{"label":"shares_sold","value":"289,774"},{"label":"weighted_average_price_usd","value":"29.16"},{"label":"min_transaction_price_usd","value":"28.98"},{"label":"max_transaction_price_usd","value":"29.36"}],"primary_claim":"On 2026-04-16, Matthew Gline sold 289,774 shares of Roivant Sciences Ltd. common stock at a weighted average price of $29.16 (with transaction prices ranging from $28.98 to $29.36).","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Roivant Sciences Ltd. (ROIV) filed a Form 4 on 2026-04-20 reporting that reporting person Matthew Gline sold 289,774 common shares on 2026-04-16 at a weighted average price of $29.16.","topics":["SEC Form 4","insider trading","common shares sale","weighted average price","transaction price range"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Roivant Sciences Ltd. \u00b7 Filed 20260420","ticker":"ROIV","tickers":["ROIV"],"title":"ROIV filed 4","url":"https://www.sec.gov/Archives/edgar/data/1635088/0001635088-26-000038.txt"}
TEXT NOT NULL
threshold
NULL
TEXT
direction
NULL
TEXT
severity
NULL
TEXT
window
NULL
TEXT
source
discovery_sec_filings
TEXT NOT NULL
reason_trace
{"_evidence_event_ids":["evt_0d0e7b9d1c2e"]}
TEXT
dedupe_key
signal_enriched:discovery_sec_filing_delta:b776d61143d3054d
TEXT NOT NULL
throttle_s
INTEGER (default 0
created_at
2026-04-21T03:09:54.871544+00:00
TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')
Update
Cancel